SCHEMBL15428004

SCHEMBL15428004

CCOC(=O)c1[nH]c2ccc(OC)cc2c1CCNC(C)=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 3/20 1.00
MTNR1A P48039 15/20 0.82
MTNR1B P49286 15/20 0.82
KDM4E B2RXH2 4/20 0.76
ALDH1A1 P00352 4/20 0.76
HPGD P15428 4/20 0.76
HSD17B10 Q99714 3/20 0.76
POLB P06746 1/20 0.76
MDM2 Q00987 1/20 0.76
CYP1A2 P05177 2/20 0.67
CYP3A4 P08684 2/20 0.67
CYP2D6 P10635 2/20 0.67
CYP2C9 P11712 2/20 0.67
CYP2C19 P33261 2/20 0.67
TSHR P16473 1/20 0.67
NPC1 O15118 1/20 0.64
MAPT P10636 1/20 0.64
RAB9A P51151 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27516969 0.88 NQO2 (0.78) NQO2MTNR1AMTNR1BKDM4EALDH1A1
SCHEMBL3221458 0.88 KDM4E (0.84) NQO2MTNR1AMTNR1BKDM4EALDH1A1
SCHEMBL16711696 0.87 NQO2 (0.76) NQO2MTNR1AMTNR1BKDM4EALDH1A1
SCHEMBL15428037 0.86 KDM4E (1.00) NQO2MTNR1AMTNR1BKDM4EALDH1A1
SCHEMBL15427770 0.86 KDM4E (0.78) NQO2MTNR1AMTNR1BKDM4EALDH1A1
SCHEMBL15428075 0.85 KDM4E (0.81) NQO2MTNR1AMTNR1BKDM4EALDH1A1
SCHEMBL15427782 0.84 KDM4E (0.79) NQO2MTNR1AMTNR1BKDM4EALDH1A1
SCHEMBL27566660 0.84 NQO2 (0.72) NQO2MTNR1AMTNR1BKDM4EALDH1A1
SCHEMBL31543713 0.84 MTNR1A (1.00) NQO2MTNR1AMTNR1BKDM4EALDH1A1
SCHEMBL8946916 0.84 MTNR1A (1.00) NQO2MTNR1AMTNR1BKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2873660-B1 INDOLECARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC (JP) 2016-10-26 EP disclosed
US-9376449-B2 Indole carboxamide derivative ASTELLAS PHARMA INC. (JP) 2016-06-28 US disclosed
US-9376449-B2 Indole carboxamide derivative ASTELLAS PHARMA INC. (JP) 2016-06-28 US disclosed
US-20150203505-A1 INDOLE CARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2015-07-23 US disclosed
US-20150203505-A1 INDOLE CARBOXAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2015-07-23 US disclosed
EP-2873660-A1 INDOLECARBOXAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2015-05-20 EP disclosed
WO-2014010602-A1 INDOLECARBOXAMIDE DERIVATIVE アステラス製薬株式会社 (JP) 2014-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203505-A1 INDOLE CARBOXAMIDE DERIVATIVE MTNR1A, MTNR1B, IDO2 NQO2 1543/4885MTNR1A 1/4885MTNR1B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.